Skip to main content

Analysts Offer Insights on Industrial Goods Companies: Transdigm Group (TDG) and MSA Safety (MSA)

Tipranks - Thu Feb 12, 6:58PM CST

There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Transdigm Group (TDGResearch Report) and MSA Safety (MSAResearch Report) with bullish sentiments.

Valentine's Day Sale - 70% Off

Transdigm Group (TDG)

In a report released yesterday, Sheila Kahyaoglu from Jefferies maintained a Buy rating on Transdigm Group, with a price target of $1565.00. The company’s shares closed last Wednesday at $1326.19.

According to TipRanks.com, Kahyaoglu is a 5-star analyst with an average return of 14.8% and a 64.7% success rate. Kahyaoglu covers the Industrial Goods sector, focusing on stocks such as Voyager Technologies, Inc. Class A, BETA Technologies, Inc. Class A, and United Airlines Holdings. ;'>

Currently, the analyst consensus on Transdigm Group is a Moderate Buy with an average price target of $1608.07, representing a 22.3% upside. In a report issued on February 3, TipRanks – OpenAI also upgraded the stock to Buy with a $1593.00 price target.

See today’s best-performing stocks on TipRanks >>

MSA Safety (MSA)

In a report released yesterday, Ross Sparenblek from William Blair maintained a Buy rating on MSA Safety. The company’s shares closed last Wednesday at $196.76, close to its 52-week high of $200.61.

According to TipRanks.com, Sparenblek is a 5-star analyst with an average return of 27.2% and a 90.9% success rate. Sparenblek covers the Industrial Goods sector, focusing on stocks such as Standex International, Enerpac Tool Group, and Federal Signal. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MSA Safety with a $200.00 average price target, representing a 2.5% upside. In a report issued on January 28, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $203.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.